Inventor · Kensington, CA, US

Marc K. Hellerstein

34Patents
16h-index
7Co-inventors
74Inventor score

Filing activity: Apr 29, 1992 → Aug 18, 2017

Most-cited inventions

PatentTitleAreaCited byStatus
US5338686A Method for measuring in vivo synthesis of biopolymers Emerging Cross-Sectional Technologies 41 Expired
US5910403A Methods for measuring cellular proliferation and destruction rates in vitro and in vivo Physics 41 Expired
US7262020B2 Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol Physics 37 Expired
US6010846A Methods for measuring cellular proliferation and destruction rates in vitro and in vivo Physics 36 Expired
US6461806B1 Methods for measuring cellular proliferation and destruction rates in vitro and in vivo Physics 33 Expired
US6808875B2 Methods for screening cellular proliferation using isotope labels Physics 30 Expired
US8005623B2 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity Physics 28 Active
US7504233B2 Methods for determining the metabolism of sugars and fats in an individual Human Necessities 28 Expired
US7449171B2 Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products Emerging Cross-Sectional Technologies 26 Expired
US7022834B2 Isotopically labelled DNA Physics 24 Expired
US7001587B2 Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water Physics 24 Expired
US7307059B2 Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water Physics 19 Expired
US7410633B2 Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water Physics 18 Active
US7255850B2 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis Human Necessities 17 Expired
US7357913B2 Methods for detecting, prognosing, or monitoring a disorder by comparing relative flux rates of two or more biological molecules in vivo Physics 17 Active
US7910323B2 Methods for identifying the effect of a drug agent on the metabolism of sugars and fats in an individual Human Necessities 16 Active
US8021644B2 Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis Human Necessities 15 Active
US8129335B2 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry Emerging Cross-Sectional Technologies 14 Active
US8481478B2 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry Emerging Cross-Sectional Technologies 10 Active
US8084016B2 Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products Emerging Cross-Sectional Technologies 8 Active
US8663602B2 Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems Emerging Cross-Sectional Technologies 7 Active
US8401800B2 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity Physics 6 Active
US8849581B2 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity Physics 6 Active
US8969287B2 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry Emerging Cross-Sectional Technologies 6 Active
US9043159B2 Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity Physics 5 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.